Sysmex (OTCMKTS:SSMXY) Shares Gap Down – Here’s What Happened

Sysmex Corporation ADR (OTCMKTS:SSMXY) gapped down prior to trading on Wednesday . The stock had previously closed at $10.02, but opened at $9.45. Sysmex shares last traded at $9.43, with a volume of 1,633 shares changing hands.

Analyst Ratings Changes

Separately, Zacks Research cut Sysmex from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Sysmex presently has a consensus rating of “Hold”.

Sysmex Stock Performance

The business’s fifty day simple moving average is $9.07 and its 200-day simple moving average is $9.06. The firm has a market cap of $5.76 billion, a P/E ratio of 24.08 and a beta of 1.07. The company has a current ratio of 3.26, a quick ratio of 2.46 and a debt-to-equity ratio of 0.12.

Sysmex (OTCMKTS:SSMXY) last issued its quarterly earnings data on Thursday, May 14th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02). The firm had revenue of $877.92 million for the quarter, compared to the consensus estimate of $862.45 million. Sysmex had a net margin of 7.13% and a return on equity of 7.23%. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. As a group, sell-side analysts expect that Sysmex Corporation ADR will post 0.42 earnings per share for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.